EP2429560B1 - Composition de stimulation immunitaire comportant un extrait d'aronia sp. en combinaison avec du sélénium - Google Patents

Composition de stimulation immunitaire comportant un extrait d'aronia sp. en combinaison avec du sélénium Download PDF

Info

Publication number
EP2429560B1
EP2429560B1 EP10720010.7A EP10720010A EP2429560B1 EP 2429560 B1 EP2429560 B1 EP 2429560B1 EP 10720010 A EP10720010 A EP 10720010A EP 2429560 B1 EP2429560 B1 EP 2429560B1
Authority
EP
European Patent Office
Prior art keywords
composition
aronia
selenium
composition according
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10720010.7A
Other languages
German (de)
English (en)
Other versions
EP2429560A1 (fr
Inventor
Klaus Eschmann
Josef Beuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ursapharm Arzneimittel GmbH
Original Assignee
Ursapharm Arzneimittel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ursapharm Arzneimittel GmbH filed Critical Ursapharm Arzneimittel GmbH
Priority to EP10720010.7A priority Critical patent/EP2429560B1/fr
Priority to PL10720010T priority patent/PL2429560T3/pl
Publication of EP2429560A1 publication Critical patent/EP2429560A1/fr
Application granted granted Critical
Publication of EP2429560B1 publication Critical patent/EP2429560B1/fr
Priority to CY20191100207T priority patent/CY1121268T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a composition comprising certain amounts of Aronia extract and selenium useful for activative macrophages in vitro, for preparation of a madicament and pharmaceutical or nutraceutical compositions comprising the same, wherein the Aronia extract is dotainable by pressing whole Aronia fruits or by concentrating Aronia juice.
  • Aronia is a deciduous shrub which belongs to the plant family Rosaceae. Within the genus Aronia several species and hybrids are known, such as Aronia melanocarpa (black chokeberry), Aronia arbutifolia (red chokeberry), and Aronia x prunifolia (purple chokeberry). The Aronia fruits are small pomes and the juice of it is known to be astringent and to have a high content of vitamin C and other antioxidants.
  • Aronia is used as a coloring agent for beverages and other food products, as disclosed e.g. in US-P- 6,703,056 , WO 2005 058052 , and WO 2006 138419 . Beside this, the Aronia fruits have awaken interest due to their antioxidative qualities.
  • Aronia melanocarpa is known to have high contents of phenolic compounds, especially anthocyanins, which are mainly located in the skin of the berries for UV protection of the pulp and the seeds. These anthocyanins give Aronia melanocarpa an extraordinary antioxidative strength.
  • a parameter showing the capacity of a compound or an extract to deal with oxidative stress is the oxygen radical absorbance capacity or ORAC.
  • Aronia shows high ORAC values and is therefore also used/added as a functional food or nutraceutical.
  • US 2007 0020358 discloses a sports drink concentrate which may include Aronia as a nutraceutical ingredient.
  • a functional sweetener composition comprising an Aronia extract as antioxidant is disclosed in WO 2007 06 1900 , and WO 2007 076857 teaches a chewing gum composition containing Aronia which is used as a source of antioxidants.
  • Aronia or compounds thereof may be used for the preparation of pharmaceutical compositions or nutraceutical compositions and food supplements.
  • DE 10 2004 029 887 A1 discloses a dietary supplement on the basis of pomace comprising an extract of the skin of Aronia fruits which dietary supplement is described to have a high radical protection factor.
  • DE 10 2004 052 882 A1 teaches a dietary supplement on the basis of a specific selection of fruit and legume concentrates, which comprises inter alia an Aronia fruit juice concentrate. Said dietary supplement is described to strengthen the immune system, wherein it is set forth that the combination of ingredients synergistically influences the impact of the ingredients.
  • WO 2001 015553 teaches that food supplements containing Aronia fruit extract may be used to inhibit an inflammation mediated by cyclooxygenase, i.e. it is disclosed that Aronia extracts have an anti-inflammatory activity due to an inhibition of COX-2 activity preferentially over COK-1 activity.
  • WO 2002 005827 teaches the use of Aronia extract for the preparation of a medicament for the treatment of brain cancer and further discloses a nutraceutical composition for the treatment of cancer comprising one or more flavonoids from Aronia and the micronutrients selenium and zinc.
  • compositions comprising an Aronia melanocarpa anthocyan extract. This extract was found to increase NK cells, the CD4/CD8 ratio, Ki-67 expressing cells and B cell numbers.
  • JP 2005-213242 discloses compositions comprising aronia extract for treating and preventing immunological disorders.
  • Micronutrients are needed and involved, e.g. as cofactors for enzymes, in a plurality of metabolism processes and are therefore important ingredients in food. Accordingly, and as taught by the prior art, micronutrients may be added to different kinds of food for example to functional food in order to achieve or improve certain physiological functions.
  • the micronutrients selenium and zinc affect beside other physiological functions the immune status.
  • Selenium is known to be required for a proper activity of neutrophils, macrophages, NK cells, T lymphocytes and some other immune mechanisms and an insufficient supply of selenium to the human body may result in a weakened immune system.
  • Zinc is known to be an important ion for enzymes, proteins and transcription factors, and is therefore involved in many functions of the body also including immune responses.
  • composition comprising an Aronia extract in an amount of at least about 10 ⁇ g/mg and selenium in an amount of from about 0.0001 ⁇ g/mg to about 2.0 ⁇ g/mg, wherein the Aronia extract is obtainable by pressing whole Aronia fruits or by concentrating Aronia juice.
  • Aronia extract is obtainable by pressing whole Aronia fruits or by concentrating Aronia juice.
  • selenium is added to the Aronia extract.
  • the amount of selenium or the combination of selenium and zinc is beyond the natural fluctuation range in an Aronia extract.
  • composition further comprises additional zinc, preferably in a concentration from about 0.0001 mg/mg to about 0.5 mg/mg.
  • composition further comprises at least one pharmaceutically or nutraceutically acceptable excipient or a mixture thereof.
  • composition is formulated as a pharmaceutical composition, preferably designed for oral, such as peroral, buccal, sublingual, mucosal, or topical administration.
  • the composition is formulated as a nutraceutical or supplementary neutraceutical composition, preferably in the form of an ingestible solution or suspension, comprising the active ingredient in dissolved or suspended form, or as a solid administration form, such as in the form of tablets, capsules, dragees, or added as a food supplement to daily food products.
  • a further embodiment is the use of the composition for the preparation of a medicament.
  • exemplary uses of such a medicament can be - without forming part of the present invention-the treatment of inflammatory diseases or conditions, bacterial infections, fungal infections, viral infections, parasitic infections and combinations thereof.
  • the inflammatory disease or condition can be preferably associated with autoimmune diseases, inflammatory bowel disease, multiple sclerosis, scleroderma, and graft-versus-host disease.
  • composition for use as a medicament and an in vitro use of the composition for activating macrophages.
  • the present invention discloses a composition which comprises a combination of an Aronia extract and the micronutrient selenium.
  • the composition may also comprise zinc as further micronutrient.
  • the Aronia extract originates from one Aronia species which is pharmaceutically and nutraceutically acceptable or is a mixture of different pharmaceutically/ nutraceutically acceptable Aronia species.
  • Aronia species that may be used include, but are not limited to A. melanocarpa, A. arbutifolia, and A. x prunifolia, wherein Aronia melanocarpa is prefered.
  • the Aronia extract may be derived from the whole fruit.
  • the extract may be based on fresh fruits or fruit juices. If desired, one or more particular active compounds may be selectively enriched in the extract.
  • An Aronia extract may be obtained to the general knowledge of the skilled person.
  • Other ways for preparing an Aronia extract are for example disclosed in DE102004029887 and DE102005046474 .
  • General extraction methods for isolating plant material is for example disclosed in FR2892933 and Ljubuncic P.et al. (J. Ethnopharmacol., Oct 3, 101(1-3) (2005),153-61 ).
  • An Aronia extract may be prepared using whole fruits as starting material.
  • the fruits are washed with water of a temperature between 30 and 50°C, preferably of 40°C and afterwards enzymatically treated with e.g. an inulinase, preferably fructozyme, for partial or complete cell disruption.
  • Suitable enzymes as well as reaction conditions are well known to the skilled person.
  • the residue obtained after pressing is extracted with aqueous potassium sulfite solution (approx. 10-30 w/v) for 1 to 3 hours at room temperature (approx. 21-24°C).
  • the extract is treated with pectin degrading enzymes, such as pectinex or pectinol, at a pH of approx. 3-4, preferably pH 3, for 0.5-2 hours.
  • the extract is distilled under vacuum at a temperature of around 40-58°C, preferably 45-50°C, yielding Aronia extract having a residual water content of approx. 30-40 w/w.
  • the composition according to the present invention comprises the Aronia extract in a concentration from at least 10 ⁇ g/mg, preferably from 20 ⁇ g/mg to 950 ⁇ g/mg. Even more preferred from 40 ⁇ g/mg to 900 ⁇ g/mg. Still more preferred is a concentration in the range from 50 ⁇ g/mg to 800 ⁇ g/mg. Still even more preferred is a concentration from 60 ⁇ g/mg to 800 ⁇ g/mg. Most preferably the Aronia extract is concentrated in a range from 80 ⁇ g/mg to 800 ⁇ g/mg.
  • a fluid composition comprises Aronia extract in a concentration of 10 ⁇ g/mg to 200 ⁇ g/mg, more preferred 60 ⁇ g/mg to 150 ⁇ g/mg and most preferred 80 ⁇ g/mg.
  • a solid or dried composition comprises Aronia extract in a concentration of 100 ⁇ g/mg to 990 ⁇ g/mg, more preferred from 300 ⁇ g/mg to 800 ⁇ g/mg, even more preferred from 400 ⁇ g/mg to 700 ⁇ g/mg and most preferred 600 ⁇ g/mg.
  • the values given are intended to mean the final concentration of the Aronia extract in the composition according to the present invention, i.e. the concentration with which the extract is administered to a patient or a subject in need thereof.
  • the composition also comprises the micronutrient selenium in an amount of from 0.001 ⁇ g/mg to 2.0 ⁇ /mg.
  • the composition comprises Aronia extract and a combination of the micronutrients selenium and zinc.
  • a micronutrient is intended to mean that additional amounts of said micronutrient(s) is/are added in addition to the micronutrients which may be already present in the Aronia extract.
  • the Aronia extract particularly from the species Aronia melanocarpa, may contain natural amounts of 4 mg/kg zinc and 20 ⁇ g/kg selenium. It will be appreciated that these natural amounts may vary dependent on the fruits specifies and growth conditions.
  • micronutrient(s) selenium or selenium and zinc may be provided for example, but not limited thereto as inorganic salts, such as chlorides, sulfates, and the like, as organic salts and other bioavailable forms, such as amino acid chelates or combinations thereof.
  • inorganic salts such as chlorides, sulfates, and the like
  • organic salts and other bioavailable forms such as amino acid chelates or combinations thereof.
  • the terms “selenium” and “zinc” are intended to comprise any compound containing selenium and zinc, respectively, including salts, complexes or other forms of said micronutrients, also including elemental selenium or zinc. Acceptable forms of selenium and zinc are well known to the skilled person. In case of given concentrations or ranges of concentrations of said micronutrients said values are intended to indicate the concentration of selenium or the selenium ion, and the concentration of zinc or the zinc ion, respectively.
  • selenium may be provided as selenomethionine, elemental selenium, various selenium salts, such selenium chloride, and selenium yeast or combinations thereof.
  • selenium is provided as selenium yeast or sodium selenite/ sodium selenate.
  • zinc may be provided as zinc acetate, zinc ascorbate, zinc chloride, zinc citrate, zinc gluconate, zinc lactate, zinc sulphate, amino acid chelated zinc, or combinations thereof.
  • the composition may be provided in liquid form or in dried/solid form, e.g. in a lyophilized form.
  • the composition can be provided in a sterile form.
  • a composition comprising an Aronia extract and additionally added selenium or additionally added selenium and zinc has an enhanced immune stimulating effect in comparison to the single compounds of the composition according to the present invention, wherein said effect does not form part of the present invention.
  • the beneficial immune stimulating effect of the composition according to the present invention is based on a synergistic effect of the complex mixture of compounds comprised in the Aronia extract in combination with the additionally added selenium.
  • a further synergistic effect may be achieved when adding zinc to the composition comprising Aronia extract and selenium.
  • composition according to the present invention has been shown to increase the macrophage activity in vitro.
  • Macrophages belong to the innate immune system which is e.g. responsible for destroying virus infected cells, parasites and tumour cells. Macrophages represent matured monocytes, which in turn belong to the white blood cells. Macrophages phagocytose and digest invading microorganisms, even protozoa, debris, foreign bodies as well as damaged, dead and senescent cells.
  • the composition according to the present invention can be used to stimulate the immune system.
  • the composition according to the present invention may be used for the preparation of a medicament for the treatment of a variety of diseases or conditions which are based on a reduced activity of the immune system, or which may be prevented or treated by stimulating the immune system.
  • diseases or conditions may be treated or prevented that are based on a reduced macrophage activity or which may be prevented or treated by enhancing the macrophage activity.
  • treatment is intended to mean prophylactic or therapeutic treatment, wherein the therapeutic treatment may be palliative or curative.
  • composition according to the present invention is characterized by an immune stimulating activity it may be also used for the preparation of a medicament designed for adjuvant therapy during the treatment of diseases which treatment is beneficially affected by stimulating the immune system. Furthermore, the composition according to the present invention may also be used for the preparation of a dietary supplement for supporting the immune system.
  • composition can be designed for the treatment of inflammatory diseases or conditions, bacterial infections, fungal infections, viral infections, parasitic infections and combinations thereof.
  • composition may be used for alleviate or improving any disorder or disease including but not limited to septic shock, haemodynamic shock, sepsis syndrome, post ischaemic reperfusion injury, inflammatory bowel disease, graft-versus-host disease, malaria, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic diseases, cachexia, graft rejection, cancers such as cutaneous T-cell lymphoma, diseases involving angiogenesis, autoimmune diseases, skin inflammatory diseases, inflammatory diseases of the eye, inflammatory bowel diseases such as Crohn's disease and colitis, osteo- and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, adult Still's disease, uveitis, Wegener's granulomatosis, Behcet disease, Sjoegren's syndrome, sarcoidosis, conjunctivitis, polymyositis, dermatomyositis, multiple s
  • bacterial or microbial infections comprise any infection with gram positive or gram negative bacteria.
  • Pathological conditions of microbial infections include, but are not limited to, conditions such as chronic upper respiratory disease, wound infection, osteomyelitis, endocarditis, skin polymicrobial infections, bronchial asthma, chronic sinusitis, cystic fibrosis or acne vulgaris.
  • fungal infections include for example blastomycosis, coccidiodomycosis, cryptococcosis, histoplasmosis, sporotrichosis, chromoblastomycosis, lobomycosis, dermatophytosis, dermatomycosis, onychomycosis, piedra, mycetoma, fusariosis, pityriasis versicolor, tinea barbae, tinea capitis, tinea corporis, tinea cruris, tinea favosa, tinea nigra, tinea pedis, phaeohyphomycosis, rhinosporidiosis, aspergillosis, mycotic keratitis, candidiasis.
  • Viral infections may be caused by viruses including, but not limited to, lentiviruses such as human immunodeficiency virus types 1 and 2 (HIV), human T-cell lymphotropic virus type 1 and 2 (HTLV-I and HTLV-II), SIV, EIAV (equine infectious anemia virus), BIV, FIV, CAEV, VMV, and MMLV (Moloney murine leukemia virus).
  • viruses including, but not limited to, lentiviruses such as human immunodeficiency virus types 1 and 2 (HIV), human T-cell lymphotropic virus type 1 and 2 (HTLV-I and HTLV-II), SIV, EIAV (equine infectious anemia virus), BIV, FIV, CAEV, VMV, and MMLV (Moloney murine leukemia virus).
  • HIV human immunodeficiency virus types 1 and 2
  • HTLV-I and HTLV-II human T-cell lymphotropic virus type 1 and 2
  • EIAV
  • Such viral infections can also be caused by hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis G virus, human foamy virus, or by human herpes viruses (e.g., herpes simplex virus type-1, herpes simplex virus type-2, herpes simplex virus type-3 (also known as Varicella-zoster virus), herpes simplex virus type-4 (also known as Epstein Barr virus or EBV), herpes simplex virus type-5, herpes simplex virus type-7).
  • herpes simplex virus type-1 herpes simplex virus type-2, herpes simplex virus type-3 (also known as Varicella-zoster virus), herpes simplex virus type-4 (also known as Epstein Barr virus or EBV), herpes simplex virus type-5, herpes simplex virus type-7).
  • herpes simplex virus type-1 e.g., herpes simplex virus type-1,
  • Such viral infections can also be caused by influenza viruses (types A, B or C), human parainfluenza viruses, respiratory syncytial virus, smallpox virus (variola virus), monkeypox virus, vaccinia virus, human papilloma virus, human parechovirus 2, mumps virus, Measles virus, Rubella virus, Semliki Forest virus, West Nile virus, Colorado tick fever virus, foot-and-mouth disease virus, Ebola virus, Marburg virus, polyomavirus, TT virus, Lassa virus, lymphocytic choriomeningitis virus, vesicular stomatitis virus, rotavirus, varicella virus, parvovirus, cytomegalovirus, encephalitis viruses, adenovirus, echovirus, rhinoviruses, filoviruses, coxachievirus, coronavirus (such as SARS-associated coronavirus), Dengue viruses, yellow fever virus, hantaviruses, regional hemorrhagi
  • parasitic infections include but are not limited to malaria.
  • Parastic infections may be caused by organisms such as protozoa, helminths, and ectoparasites.
  • Selenium is added as a micronutrient to the composition comprising Aronia extract. Selenium is added in one or more suitable form(s) as set forth above.
  • selenium is added to the composition to a final concentration from 0.0001 ⁇ g/mg to 2.0 ⁇ g/mg.
  • selenium may be added to the composition in a range from 0.0005 ⁇ g/mg to 1.0 ⁇ g/mg. Even more preferred from 0.001 ⁇ g/mg to 0.5 ⁇ g/mg. Still more preferred is a concentration ranging from 0.001 ⁇ g/mg to 0.25 ⁇ g/mg. Even still more preferred is a concentration ranging from 0.001 ⁇ g/mg to 0.2 ⁇ g/mg. Most preferred is a concentration between 0.0012 ⁇ g/mg to 0.1 ⁇ g/mg.
  • a fluid composition of the present invention comprises selenium in a concentration from 0.0001 ⁇ g/mg to 0.01 ⁇ g/mg, more preferably from 0.0005 ⁇ g/mg to 0.005 ⁇ g/mg, most preferably from 0.0008 ⁇ g/mg to 0.003 ⁇ g/mg and even most preferably 0.0012 ⁇ g/mg.
  • a solid or dried composition may comprise selenium in a concentration from 0.001 ⁇ g/mg to 0.5 ⁇ g/mg, more preferably from 0.005 ⁇ g/mg to 0.01 ⁇ g/mg, most preferably from 0.003 ⁇ g/mg to 0.02 ⁇ g/mg and even most preferably 0.01 ⁇ g/mg.
  • the values given are intended to mean the final concentration of added selenium in the composition according to the present invention, i.e. the concentration with which the added selenium is administered to a patient or a subject in need thereof.
  • the final concentration of selenium added to the composition according to the present invention may be chosen also in view of the daily requirement amounts of selenium. Accordingly, factors like for example the intended way of administration, and the amount/dosage of the composition given per day and subject, may be considered. Such considerations are within the general knowledge of the skilled person.
  • zinc may be added to the composition comprising Aronia extract and selenium, in one or more suitable forms as set forth above, to formulate a composition according to the present invention.
  • Zinc may be added to the composition of the present invention in a concentration from 0.0001 mg/mg to 0.5 mg/mg.
  • zinc may be added to the composition in a range from 0.0005 mg/mg to 0.1 mg/mg. Even more preferred from 0.001 mg/mg to 0.08 mg/mg. Still more preferred is a concentration ranging from 0.0015 mg/mg to 0.006 mg/mg. Even still more preferred is a concentration ranging from 0.002 mg/mg to 0.04 mg/mg.
  • the values given are intended to mean the final concentration of the added zinc in the composition according to the present invention, i.e. the concentration with which the added zinc is administered to a patient or a subject in need thereof.
  • the final concentration of zinc added to the composition according to the present invention may be selected also in view of the daily requirement amounts of zinc. Accordingly, factors like for example the intended way of administration and the amount/dosage of the composition given per day and subject, may be considered. Such considerations are within the general knowledge of the skilled person.
  • each of the micronutrients may be added in a concentration or a concentration range as given above.
  • composition according to the present invention may be administered by itself, for example in liquid or in solid form, or may be formulated as pharmaceutical composition or as nutraceutical composition.
  • Said pharmaceutical composition or nutraceutical composition comprises as an active ingredient a composition according to the present invention and at least one pharmaceutically/ nutraceutically acceptable excipient or a mixture of pharmaceutically/ nutraceutically acceptable excipients.
  • Suitable excipients include, but are not limited to diluents, carriers, disintegrants, binders, glidants, lubricants, coating agents and the like or mixtures thereof, which might be needed for the preparation of final dosage forms.
  • the pharmaceutical or nutraceutical compositions according to the present invention may be prepared by mixing the active ingredient, optionally in combination with other active compounds, with one or more suitable excipient(s) by methods which are well known to the skilled person.
  • the pharmaceutical or nutraceutical compositions are prepared under sterile conditions.
  • the pharmaceutical composition or nutraceutical composition according to the present invention may comprise from 1 % to 99 % by weight of said pharmaceutically acceptable excipient(s), preferably from 10 % to 95 % by weight, and most preferably from 20 % to 75 % by weight.
  • excipient(s) The selection of one or more appropriate excipient(s) and their respective amounts is within the general knowledge of the skilled person.
  • the excipient(s) may be selected with regard to the intended route of administration.
  • the pharmaceutical or nutraceutical compositions according to the present invention may be formulated in a variety of ways to be administered to humans and/or animals.
  • the pharmaceutical or nutraceutical composition according to the present invention may be formulated in a liquid form, i.e. for example in the form of solutions, dispersions, emulsions and gels, or in a solid form.
  • the pharmaceutical composition as well as the nutraceutical composition may be designed for immediate release and/or for sustained release. Accordingly, also depot forms of the composition according to the present invention are described herein.
  • the composition is formulated as a pharmaceutical composition.
  • Said pharmaceutical composition comprises a therapeutically effective amount of a composition according to the present invention together with one or more pharmaceutically acceptable excipient(s).
  • a therapeutically effective amount of a composition according to the present invention is an amount that when administered to a patient or a subject in need thereof is capable of exerting an effect.
  • a pharmaceutical composition according to the present invention may be formulated for oral, such as peroral, buccal, sublingual, or mucosal administration, or for topical administration.
  • said pharmaceutical composition is designed for oral administration.
  • a pharmaceutical composition may be designed as an ingestable solution or suspension, comprising the active ingredient in dissolved or suspended form, or as a solid administration form, such as for example tablets, capsules, dragees, powders, granules.
  • said pharmaceutical composition is designed for topical administration.
  • Topical administration may be achieved for example, but not limiting the present invention thereto, in the form of ointments, creams, lotions, solutions, and elixirs.
  • composition according to the present invention may well be used for the preparation of a nutraceutical composition. Therefore, and in accordance with another preferred embodiment of the present invention the composition is formulated as a nutraceutical composition.
  • nutraceutical composition is intended to mean a composition that may be considered as food or a food supplement, which is used to improve the diet in order to provide well-being, health benefits.
  • a pharmaceutical/ nutraceutical composition according to the present invention comprises an effective amount of a composition according to the present invention together with one or more pharmaceutically/ nutraceutically acceptable excipient(s).
  • An effective amount of a composition according to the present invention is an amount that when administered to a subject in need thereof is capable of exerting an effect.
  • nutraceutical composition according to the present invention may be formulated for oral, such as peroral, buccal, sublingual, or mucosal administration.
  • nutraceutical composition is designed for oral administration.
  • a nutraceutical composition for oral administration may be designed as an ingestable solution or suspension, comprising the active ingredient in dissolved or suspended form, or as a solid administration form, such as in the form of tablets, capsules, dragees.
  • the nutraceutical composition according to the present invention may be formulated to be added as a food supplement to daily food products.
  • the nutraceutical composition may be added to beverages, cereals, etc.
  • the amount to be administered depends on the subject to be treated taking into account its age, weight and other personal conditions.
  • Fresh-frozen Aronia fruits have been used for preparing the Aronia extract (botanical species: Aronia melanocarpa ).
  • the aqueous pressed juice was concentrated to obtain a ratio of fruits to pressed juice concentrate (native) of 8-10 to 1.
  • Cells Cell line (RAW 264.7, murine macrophages) was purchased from the America Type Culture Collection and cultivated as recommended.
  • HBSS Hank's Balanced Salt Solution
  • HBSS Hank's Balanced Salt Solution
  • HBSS Hank's Balanced Salt Solution
  • This stock solution was further diluted in HBSS prior to use.
  • 1 ml cells (5 x 10 6 cells/ml) were incubated with 0.1 ml solution of Aronia extract and Aronia extract together with sodium selenite (dosis kinetics for each component and the combinations as documented in the figures). All these constituents were kept in an incubator (37°C, 5% CO 2 ) for 30 min, then centrifuged at 1200 U/min for 5 min and resuspended in minimal essential medium (MEM, Gibco Co.).
  • MEM minimal essential medium
  • the reaction mixture consisted of a suspension (0.25 ml) at a concentration of 5 x 10 6 PMNL (polymorphonuclear leucocytes)/ml respectively monocytes/macrophages, 50 ⁇ l zymosan, and 0.45 ml medium containing 2 x 10 -6 M lucigenine.
  • the reaction mixture was kept at 37°C before chemoluminescence measurements were performed with a Luminometer (Luminoskan 1251, Labsystems) according to manufacturer's instructions (User's Manual 1995).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)

Claims (11)

  1. Composition comprenant un extrait d'Aronia dans une quantité d'au moins 10µg/mg et du sélénium dans une quantité de 0,0001 µg/mg à 2.0 µg/mg, dans laquelle l'extrait d'Aronia est obtenu en pressant l'ensemble des fruits d'Aronia ou en concentrant le jus d'Aronia.
  2. Composition selon la revendication 1, comprenant en outre du zinc additionnel.
  3. Composition selon la revendication 2, comprenant du zinc à une concentration comprise entre 0,0001 mg/mg et 0,5 mg/mg.
  4. Composition selon l'une des revendications précédentes, dans laquelle la composition comprend en outre au moins un excipient ou un mélange de ceux-ci pharmaceutiquement acceptable ou nutraceutiquement acceptable.
  5. Composition selon la revendication 4, dans laquelle la composition est formulée en tant que composition pharmaceutique.
  6. Composition selon la revendication 5 conçue ou formulée pour une administration orale, buccale, sublinguale, par voie muqueuse ou topique.
  7. Composition selon la revendication 4, dans laquelle la composition est formulée en tant que composition nutraceutique ou composition nutraceutique complémentaire.
  8. Composition selon la revendication 7, conçue en tant que solution ou suspension pouvant être ingérée, comprenant l'ingrédient actif dans une forme dissoute ou suspendue, ou en tant qu'administration sous forme solide, prenant la forme de comprimés, de capsules, de dragées ou ajoutée en tant que complément alimentaire dans des produits alimentaires quotidiens.
  9. Utilisation de la composition selon l'une des revendications 1 à 5 pour la préparation d'un médicament.
  10. Composition selon l'une des revendications 1 à 5 pour une utilisation en tant que médicament.
  11. Utilisation in vitro de la composition selon l'une des revendications 1 à 5 pour activer les macrophages.
EP10720010.7A 2009-05-12 2010-05-06 Composition de stimulation immunitaire comportant un extrait d'aronia sp. en combinaison avec du sélénium Active EP2429560B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP10720010.7A EP2429560B1 (fr) 2009-05-12 2010-05-06 Composition de stimulation immunitaire comportant un extrait d'aronia sp. en combinaison avec du sélénium
PL10720010T PL2429560T3 (pl) 2009-05-12 2010-05-06 Kompozycja stymulująca układ odpornościowy zawierająca ekstrakt z aronia sp. w połączeniu z selenem
CY20191100207T CY1121268T1 (el) 2009-05-12 2019-02-14 Ανοσοδιεγερτικη συνθεση που περιλαμβανει εκχυλισμα aronia sp. σε συνδυασμο με σεληνιο

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09006414A EP2260856A1 (fr) 2009-05-12 2009-05-12 Composition de stimulation immunitaire comportant un extrait d'arona s en combinaison avec du sélénium et/ou du zinc
EP10720010.7A EP2429560B1 (fr) 2009-05-12 2010-05-06 Composition de stimulation immunitaire comportant un extrait d'aronia sp. en combinaison avec du sélénium
PCT/EP2010/056190 WO2010130629A1 (fr) 2009-05-12 2010-05-06 Composition de stimulation immunitaire comprenant un extrait d'aronia sp. en combinaison avec du sélénium et/ou du zinc

Publications (2)

Publication Number Publication Date
EP2429560A1 EP2429560A1 (fr) 2012-03-21
EP2429560B1 true EP2429560B1 (fr) 2018-11-14

Family

ID=41228588

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09006414A Withdrawn EP2260856A1 (fr) 2009-05-12 2009-05-12 Composition de stimulation immunitaire comportant un extrait d'arona s en combinaison avec du sélénium et/ou du zinc
EP10720010.7A Active EP2429560B1 (fr) 2009-05-12 2010-05-06 Composition de stimulation immunitaire comportant un extrait d'aronia sp. en combinaison avec du sélénium

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09006414A Withdrawn EP2260856A1 (fr) 2009-05-12 2009-05-12 Composition de stimulation immunitaire comportant un extrait d'arona s en combinaison avec du sélénium et/ou du zinc

Country Status (14)

Country Link
US (2) US20120148683A1 (fr)
EP (2) EP2260856A1 (fr)
JP (1) JP5612670B2 (fr)
CN (2) CN102421446A (fr)
CA (1) CA2757759C (fr)
CY (1) CY1121268T1 (fr)
DK (1) DK2429560T3 (fr)
ES (1) ES2704025T3 (fr)
LT (1) LT2429560T (fr)
MX (1) MX347299B (fr)
PL (1) PL2429560T3 (fr)
PT (1) PT2429560T (fr)
TR (1) TR201818784T4 (fr)
WO (1) WO2010130629A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013138633A (ja) * 2011-12-28 2013-07-18 Pola Chemical Industries Inc 液状食品組成物の澱発生防止方法
CN103417668A (zh) * 2013-07-29 2013-12-04 辽宁大学 西伯利亚花楸果实提取物在制备抗HeLa癌细胞的药品或保健品中的应用
CN105434465B (zh) * 2015-12-14 2019-07-16 米军 一种防治关节炎的药物组合物及其制备方法
JP6961100B2 (ja) * 2017-10-27 2021-11-05 ジェイビーケーラブ カンパニー リミテッドJbklab Co., Ltd. アントシアニン−フコイダン複合体を有効成分として含有する免疫増強剤、免疫抗ガン剤及び抗ガン剤の副作用緩和剤
US10568866B1 (en) * 2018-10-05 2020-02-25 Matthias W. Rath Composition and its use for increasing innate immune health
CN109248202A (zh) * 2018-11-14 2019-01-22 吉林大学 一种花楸果及其提取物在制备抗病毒性肝炎药物中的应用
CN115105527A (zh) * 2022-07-01 2022-09-27 湖北省疾病预防控制中心（湖北省预防医学科学院） 药物组合物及其用途
CN116270822B (zh) * 2023-04-21 2024-03-15 广东冠清柠生物科技有限公司 一种缓解肺部纤维化的植物提取物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300288A (en) * 1991-04-05 1994-04-05 Rohm And Haas Company Composition and method for controlling cholesterol
EP1005863A1 (fr) * 1998-12-04 2000-06-07 Synthelabo Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
KR20060123663A (ko) 1999-08-27 2006-12-01 미시간 스테이트 유니버시티 천연 사이클로옥시게나제 저해물질을 함유하는 조성물
WO2002005827A2 (fr) 2000-07-18 2002-01-24 Forum Bioscience Traitement anticancéreux à base de produits naturels
US6703056B2 (en) 2000-09-29 2004-03-09 The Procter + Gamble Co. Beverage compositions comprising arabinogalactan and defined minerals
RU2236244C2 (ru) * 2001-12-27 2004-09-20 Тулев Юрий Владимирович Иммунотропный препарат "витулин в"
DE102004029887A1 (de) 2003-06-23 2005-01-20 Norbert Groth Nahrungsergänzungsmittel auf Tresterbasis
US20050129825A1 (en) 2003-12-16 2005-06-16 Gray Kimberley H. Stabilization of milk-based products
JP2005213242A (ja) * 2004-02-02 2005-08-11 Shonan Institute For Medical & Preventive Science シクロオキシゲナーゼ及び誘導型一酸化窒素合成酵素の阻害剤及び食品
JP4247833B2 (ja) * 2004-03-16 2009-04-02 株式会社ケーツーコミュニケーションズ 視機能改善剤
US7964234B2 (en) * 2004-10-28 2011-06-21 Neways, Inc. High mineral content dietary supplement
DE102004052882A1 (de) 2004-11-02 2006-05-04 Ihv Internationale Handels- Und Vertriebsgesellschaft Mbh Nahrungsergänzungsmittel und Herstellungsverfahren dafür
US20070020358A1 (en) 2005-03-18 2007-01-25 Mower Thomas E Sports drink concentrate
US7749545B2 (en) * 2005-03-18 2010-07-06 Sakura Properties, Llc Fucoidan compositions and methods for dietary and nutritional supplements
US20060286207A1 (en) 2005-06-14 2006-12-21 Gray Kimberley H Stabilization of malt-based and hops-based products
DE102005046474A1 (de) 2005-07-15 2007-01-18 Norbert Groth Verwendung eines Schalenextraktes aus Aronia sp. als antibakterielles, antimykotisches und entzündungshemmendes Mittel
FR2892933B1 (fr) 2005-11-10 2010-11-05 Herve Andre Gerard Durand Extrait vegetal obtenu par un procede d'extraction a l'aide de solvants d'origine vegetale
US20080292607A1 (en) * 2005-11-23 2008-11-27 Elizabeth Mazzio Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
US8962058B2 (en) 2005-11-23 2015-02-24 The Coca-Cola Company High-potency sweetener composition with antioxidant and compositions sweetened therewith
EP1976391B1 (fr) 2005-12-30 2010-10-20 Cadbury Holdings Limited Composition de gomme a macher contenant de l'aronia
US20070269576A1 (en) * 2006-05-18 2007-11-22 Brent Barton Exotic fruit juice and silver-containing beverage
JP2007306898A (ja) * 2006-05-22 2007-11-29 Woc:Kk 冬虫夏草を用いた機能性食品とその製造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Extract", 12 February 2009 (2009-02-12), pages 1 - 3, Retrieved from the Internet <URL:https://en.wikipedia.org/wiki/Extract> [retrieved on 20171211] *
"Lexikon der Biologie", vol. 4, 1999, SPEKTRUM, AKAD. VERL., Heidelberg, ISBN: 3-8274-0326-X, pages: 304 - 304 *
WYK B.-E., WINK M.: "MEDICINAL PLANTS OF THE WORLD", 2005, TIMBER PRESS, Portland, Oregon, ISBN: 0-88192-602-7, pages: 18 - 18 *

Also Published As

Publication number Publication date
PT2429560T (pt) 2019-02-01
EP2260856A1 (fr) 2010-12-15
MX347299B (es) 2017-04-21
CA2757759A1 (fr) 2010-11-18
JP2012526083A (ja) 2012-10-25
TR201818784T4 (tr) 2019-01-21
PL2429560T3 (pl) 2019-04-30
CY1121268T1 (el) 2020-05-29
CA2757759C (fr) 2016-12-20
WO2010130629A1 (fr) 2010-11-18
MX2011011860A (es) 2011-12-08
ES2704025T3 (es) 2019-03-13
US20120148683A1 (en) 2012-06-14
CN103845449A (zh) 2014-06-11
US10293014B2 (en) 2019-05-21
US20150132418A1 (en) 2015-05-14
JP5612670B2 (ja) 2014-10-22
CN102421446A (zh) 2012-04-18
LT2429560T (lt) 2018-12-10
DK2429560T3 (en) 2019-02-18
EP2429560A1 (fr) 2012-03-21

Similar Documents

Publication Publication Date Title
US10293014B2 (en) Immune stimulating composition comprising an extract of Aronia sp. in combination with selenium and/or zinc
Ravi et al. The beneficial effects of Spirulina focusing on its immunomodulatory and antioxidant properties
Mohan et al. Spirulina, the nature’s wonder: A review
Maiti et al. Therapeutic potentials of andrographolide from Andrographis paniculata: a review
Zhang et al. A primary study of the antioxidant, hypoglycemic, hypolipidemic, and antitumor activities of ethanol extract of brown slimecap mushroom, Chroogomphus rutilus (Agaricomycetes)
Foong et al. Biological properties of cucumber (Cucumis sativus L.) extracts
EP2682123B1 (fr) Additif bioactif destiné à la normalisation de la fonction de la glande thyroïde
Ang et al. Brine shrimp lethality and antioxidant activity of the leaf, rind and seed ethanolic extracts of Durio zibethinus L
EP3277260B1 (fr) Extraits végétaux de crassifolium erodium l&#39;her et leurs utilisations
Haque et al. Antibacterial properties of Neem (Azadirachta indica): a mini review
KR20120044807A (ko) 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물
Baldi et al. Amelioration of in-vivo antioxidant activity by banana extracts
KR102070362B1 (ko) 꿀벌의 면역증강용 조성물 및 그의 제조방법
KR20040031799A (ko) 반도심층수 농축물을 함유한 항알러지 활성을 갖는약학조성물
WO2012093919A2 (fr) Composition de traitement de la leucémie et procédé de préparation d&#39;extrait de myrrhe
KR20150104950A (ko) 헤스페레틴 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 방사선에 의한 세포 또는 조직 손상 예방 및 치료용 약학적 조성물
KR20180041400A (ko) 락토바실러스 사케이 k040706을 함유하는 바이러스 감염 질환 예방 또는 치료용 조성물
KR20050024920A (ko) 불미나리 엽록소 및 인진쑥꽃 분말 함유 정제형건강보조식품 및 그 제조방법
Assumpta et al. Anti-ulcerogenic and membrane stabilization effect of ethanol extract of coconut (Cocos nucifera)
Hamilton-Amachree et al. Phytochemical analysis and assessment of the antibacterial and antioxidant activities of the aqueous and ethanolic leaf extracts of life plant (kalanchoe pinnata l.) in the Niger Delta Nigeria
KR20080061619A (ko) 백영고버섯 추출물을 함유하는 항암 약제조성물
KR101745126B1 (ko) 혼합 생약재 추출물을 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 조성물
CN116350555A (zh) 一种具有抗病毒作用的漱口水及其制备方法
SK1612021U1 (sk) Ovocný nápoj s pozitívnym vplyvom na zdravie človeka
Chandulal et al. Pomegranate: Natural remedy for treating periodontal disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130114

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180629

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1064005

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010055068

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2429560

Country of ref document: PT

Date of ref document: 20190201

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190123

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190212

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2704025

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190314

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190214

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190214

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181114

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190400439

Country of ref document: GR

Effective date: 20190509

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E017576

Country of ref document: EE

Effective date: 20190208

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010055068

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181114

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181114

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190815

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181114

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010055068

Country of ref document: DE

Representative=s name: 2K PATENT- UND RECHTSANWAELTE PARTNERSCHAFT MB, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100506

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1064005

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181114

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230315

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20230517

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20230428

Year of fee payment: 14

Ref country code: NL

Payment date: 20230519

Year of fee payment: 14

Ref country code: MC

Payment date: 20230517

Year of fee payment: 14

Ref country code: LT

Payment date: 20230420

Year of fee payment: 14

Ref country code: IT

Payment date: 20230531

Year of fee payment: 14

Ref country code: IE

Payment date: 20230516

Year of fee payment: 14

Ref country code: FR

Payment date: 20230517

Year of fee payment: 14

Ref country code: ES

Payment date: 20230621

Year of fee payment: 14

Ref country code: EE

Payment date: 20230518

Year of fee payment: 14

Ref country code: DK

Payment date: 20230522

Year of fee payment: 14

Ref country code: DE

Payment date: 20230531

Year of fee payment: 14

Ref country code: CZ

Payment date: 20230424

Year of fee payment: 14

Ref country code: CY

Payment date: 20230505

Year of fee payment: 14

Ref country code: CH

Payment date: 20230605

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230428

Year of fee payment: 14

Ref country code: SK

Payment date: 20230502

Year of fee payment: 14

Ref country code: PL

Payment date: 20230424

Year of fee payment: 14

Ref country code: LV

Payment date: 20230517

Year of fee payment: 14

Ref country code: GR

Payment date: 20230516

Year of fee payment: 14

Ref country code: FI

Payment date: 20230523

Year of fee payment: 14

Ref country code: AT

Payment date: 20230516

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20230517

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20230522

Year of fee payment: 14

Ref country code: GB

Payment date: 20230522

Year of fee payment: 14